UM  > 健康科學學院
Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial
Chuan Yue Wang1; Xiang Yutao2; Zhuo-Ji Cai3; Yong-Zhen Weng4; Qi-Jing Bo5; Jing-Ping Zhao6; Tie-Qiao Liu3; Gao-Hua Wang2; Shi-Min Weng6; Hong-Yan Zhang6; Da-Fang Chen6; Wai-Kwong Tang6; Gabor S. Ungvari6
2010
Source PublicationAMERICAN JOURNAL OF PSYCHIATRY
ISSN0002-953X
Volume167Issue:6Pages:676-685
Abstract

Objective: Prevention of relapse is the crucial task in the maintenance treatment of schizophrenia. The investigators in this study sought to determine the duration of maintenance treatment needed with the initial therapeutic dose, in contrast to a reduced dose. 

Method: In a multicenter open-label, randomized, controlled study, patients with schizophrenia who were clinically stabilized following an acute episode were randomly assigned to a no-dose-reduction group (initial optimal therapeutic dose continued throughout the study), a 4-week group (initial optimal therapeutic dose continued for 4 weeks, followed by a 50% dose reduction that was maintained until the end of the study), or a 26-week group (initial optimal therapeutic dose continued for 26 weeks, followed by a 50% dose reduction until the end of the study). All patients continued until the last recruited patient completed the 1-year follow-up. 

Results: Of the 404 patients who met the entry criteria and were randomly assigned, 374 completed the study. The estimated mean time from entry to relapse was 571 days in the 4-week group, 615 days in the 26-week group, and 683 days in the no-dose-reduction group, with estimated relapse rates of 30.5%, 19.5%, and 9.4%, respectively. Patients in the nodose- reduction group experienced greater reduction in the severity of psychotic symptoms. 

Conclusions: Patients who continued to receive the full risperidone dose used for their acute episode had fewer relapses than those who had dose reductions after 4 weeks or 26 weeks during the maintenance period. There was negligible difference in side effects among the three groups. (Am J Psychiatry 2010;167:676-685)

DOIhttps://doi.org/10.1176/appi.ajp.2009.09030358
Indexed BySCI
Language英语
WOS Research AreaPsychiatry
WOS SubjectPsychiatry
WOS IDWOS:000278269500012
Fulltext Access
Citation statistics
Cited Times [WOS]:40   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionFaculty of Health Sciences
Affiliation1.Beijing Anding Hospital, Capital Medical University, Beijing
2.Department of Psychiatry, Chinese University of Hong Kong
3.Mental Health Institute, Second Xiangya Hospital, Central South University, Changsha, China
4.Department of Psychiatry, Renmin Hospital, Wuhan University, Wuhan, China; the Shanghai Mental Health Center, Shanghai
5.Shanghai Mental Health Center, Shanghai
6.Institute of Mental Health and the School of Public Health, Peking University, Beijing
Recommended Citation
GB/T 7714
Chuan Yue Wang,Xiang Yutao,Zhuo-Ji Cai,et al. Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial[J]. AMERICAN JOURNAL OF PSYCHIATRY,2010,167(6):676-685.
APA Chuan Yue Wang.,Xiang Yutao.,Zhuo-Ji Cai.,Yong-Zhen Weng.,Qi-Jing Bo.,...&Gabor S. Ungvari.(2010).Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial.AMERICAN JOURNAL OF PSYCHIATRY,167(6),676-685.
MLA Chuan Yue Wang,et al."Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial".AMERICAN JOURNAL OF PSYCHIATRY 167.6(2010):676-685.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Chuan Yue Wang]'s Articles
[Xiang Yutao]'s Articles
[Zhuo-Ji Cai]'s Articles
Baidu academic
Similar articles in Baidu academic
[Chuan Yue Wang]'s Articles
[Xiang Yutao]'s Articles
[Zhuo-Ji Cai]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Chuan Yue Wang]'s Articles
[Xiang Yutao]'s Articles
[Zhuo-Ji Cai]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.